By: IPP Bureau
Last updated : June 17, 2026 9:50 am
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
ARScience Biotherapeutics, a clinical-stage biotechnology company focused on customized interleukins for in vivo use, has appointed Gustavo Mahler as its Chief Executive Officer, effective July 1, 2026.
Mahler, who previously served on the company's Board of Directors, brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management.
Most recently, he served as CEO of Cellistic and Ncardia, where he led strategic growth initiatives in the induced pluripotent stem cell (iPSC) sector and advanced cell therapy development and manufacturing capabilities.
Prior to that, Mahler was a Venture Partner at Dynamk Capital, focusing on investments in life sciences technologies and services. He also spent a decade leading AGC Biologics, helping transform it into a leading global contract development and manufacturing organization, and held senior leadership roles at Bayer Healthcare.
“I am truly excited to step into the CEO role at ARScience Biotherapeutics at such a pivotal moment. I look forward to accelerating our programs and forging the partnerships that will bring these customized cytokine solutions to the patients who need them,” said Mahler.
Commenting on the appointment, Claudia Zylberberg said, “Gustavo’s appointment as CEO is a significant milestone for ARScience. His rare combination of deep scientific knowledge—particularly in cell therapy and biotherapeutic development—with proven commercial and operational leadership makes him the ideal executive to lead our company into its next chapter.”